Antiretroviral therapy and resistance to antiretroviral drugs

被引:0
|
作者
Lange, JMA [1 ]
van Leeuwen, R [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Int Antiviral Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Slightly more than a decade after the discovery of HIV as the causative agent of AIDS, effective therapies against this virus have become available. Because of a large degree of cross-resistance among antiretroviral agents in the same class (nRTIs, NNRTIs, or PIs), once a therapy has failed virologically, future therapeutic options with currently available drugs are limited, however. Poor tolerability and toxicity may also compromise the long-term prospects of antiretroviral therapy. Nevertheless, benefits of antiretroviral therapy far outweigh the downsides and efforts to scale up responisble use of antiretroviral agents in developing countries are a priority in the fight against HIV/ AIDS. This paper presents an overview of antiretroviral therapy and resistance to antiretroviral drugs.
引用
收藏
页码:51 / 75
页数:25
相关论文
共 50 条
  • [31] Antiretroviral TherapyOptimal Sequencing of Therapy to Avoid Resistance
    Jorge L. Martinez-Cajas
    Mark A. Wainberg
    [J]. Drugs, 2008, 68 : 43 - 72
  • [32] Genotypic-resistance assays and antiretroviral therapy
    Deeks, SG
    Abrams, DI
    [J]. LANCET, 1997, 349 (9064): : 1489 - 1490
  • [33] Adherence, viral suppression, and resistance to antiretroviral therapy
    Bangsberg, David R.
    [J]. AIDS READER, 2007, 17 (04): : S11 - S15
  • [34] Resisting resistance: Maximizing the durability of antiretroviral therapy
    Condra, JH
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (11) : 951 - 954
  • [35] Drug resistance in antiretroviral therapy of HIV infection
    Oette, M
    Häussinger, D
    [J]. MEDIZINISCHE KLINIK, 2003, 98 (12): : 692 - 699
  • [36] Antiretroviral drug resistance and routine therapy, Cameroon
    Laurent, C
    Kouanfack, C
    Vergne, L
    Tardy, M
    Zekeng, L
    Noumsi, N
    Butel, C
    Bourgeois, A
    Mpoudi-Ngolé, E
    Koulla-Shiro, S
    Peeters, M
    Delaporte, E
    [J]. EMERGING INFECTIOUS DISEASES, 2006, 12 (06) : 1001 - 1004
  • [37] HIV resistance and tolerability issues in antiretroviral therapy
    Idemyor, V
    [J]. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2001, 93 (04) : 151 - 153
  • [38] Resistance to antiretroviral therapy among patients in Uganda
    Weidle, PJ
    Kityo, CM
    Mugyenyi, P
    Downing, R
    Kebba, A
    Pieniazek, D
    Respess, R
    Hertogs, K
    De Vroey, V
    Dehertogh, P
    Bloor, S
    Larder, B
    Lackritz, E
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (05): : 495 - 500
  • [39] Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
    Karim, Salim S. Abdool
    Naidoo, Kogieleum
    Grobler, Anneke
    Padayatchi, Nesri
    Baxter, Cheryl
    Gray, Andrew
    Gengiah, Tanuja
    Nair, Gonasagrie
    Bamber, Sheila
    Singh, Aarthi
    Khan, Munira
    Pienaar, Jacqueline
    El-Sadr, Wafaa
    Friedland, Gerald
    Karim, Quarraisha Abdool
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (08): : 697 - 706
  • [40] Antiretroviral therapy: When to start and which drugs to use
    Anderson A.M.L.
    Lennox J.L.
    [J]. Current Infectious Disease Reports, 2008, 10 (4) : 332 - 339